PPARA and Disorder of lipid metabolism: In this investigation, both LJF and CGA improved HFD-induced prediabetes with IGT and lipid metabolism disorders such as decreasing plasma LDL-C and liver TC, attenuating the reduction of plasma HDL-C, VLCFA-containing ceramides species and PUFA-containing DAG species, which may be through the CTRPs-AdipoR1/2-AMPK/PPARα signaling pathway.